Want to see BHVN full AI Analyst Report?
Top Page
Biohaven Ltd.
(NYSE:BHVN)
Select Model
Select Model
Rating:56Neutral
Price Target:
$17.00
▲(18.22% Upside)
Action:Reiterated
Date:10/30/26
The score is held down primarily by weak financial performance (pre-revenue, large ongoing losses and cash burn, and a deteriorated balance sheet with negative equity). Offsetting factors include strong technical momentum (price above major moving averages with positive MACD) and generally favorable corporate developments (NDA review acceptance and sizable non-dilutive licensing capital), though tempered by the partial FDA hold on BHV-7000. Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Non-dilutive Kv7 licensing
The SK partnership converts the Kv7 platform into substantial non-dilutive funding while preserving royalty participation. By transferring commercialization responsibilities and receiving milestone potential, Biohaven can support broader pipeline development with less reliance on equity financing.
Negative Factors
Pre-revenue operating model
Biohaven has not yet demonstrated commercial revenue or positive unit economics, leaving its financial profile dependent on pipeline progress and partnership proceeds. Persistent losses reduce internal funding capacity and make future profitability reliant on successful development and commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive Kv7 licensing
The SK partnership converts the Kv7 platform into substantial non-dilutive funding while preserving royalty participation. By transferring commercialization responsibilities and receiving milestone potential, Biohaven can support broader pipeline development with less reliance on equity financing.
Read all positive factors
Biohaven Ltd. (BHVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.33B
Dividend YieldN/A
Average Volume (3M)3.41M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue GrowthN/A
EPS Growth49.16%
CountryUS
Employees274
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.86
Shares Outstanding151,043,780
10 Day Avg. Volume5,195,822
30 Day Avg. Volume3,411,000
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.24K
Enterprise Value/Ebitda-4.05
Forecast
1Y Price Target
$26.00Price Target Upside80.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.34
Revenue Forecast (FY)$130.71M
Biohaven Ltd. Business Overview & Revenue Model
Company Description
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial...
How the Company Makes Money
Biohaven’s revenue model (where disclosed) has historically been driven primarily by collaboration and licensing economics rather than broad, internally built commercial product sales. Key ways the company has made money include: (1) Upfront payme...
Biohaven Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -960.00K | -4.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -532.30M | -727.46M | -837.83M | -402.64M | -568.46M | -211.04M |
| Net Income | -542.68M | -738.82M | -846.42M | -408.17M | -570.28M | -213.80M |
Balance Sheet | ||||||
| Total Assets | 263.68M | 451.45M | 615.11M | 513.21M | 661.78M | 142.06M |
| Cash, Cash Equivalents and Short-Term Investments | 161.13M | 319.14M | 485.99M | 381.82M | 465.34M | 76.06M |
| Total Debt | 300.44M | 284.61M | 36.58M | 30.88M | 33.60M | 2.80M |
| Total Liabilities | 361.92M | 399.38M | 191.67M | 85.24M | 123.01M | 47.37M |
| Stockholders Equity | -98.25M | 52.07M | 423.44M | 427.98M | 538.77M | 34.69M |
Cash Flow | ||||||
| Free Cash Flow | -473.17M | -610.15M | -586.50M | -334.77M | -338.76M | -146.78M |
| Operating Cash Flow | -472.53M | -609.44M | -582.45M | -331.73M | -297.69M | -145.84M |
| Investing Cash Flow | 10.96M | 300.56M | -244.97M | 129.83M | -304.79M | 944.00K |
| Financing Cash Flow | 371.82M | 439.12M | 677.77M | 211.91M | 767.60M | 138.45M |
Biohaven Ltd. Technical Analysis
Positive
14.38
Price Trends
13.62
Positive
14.01
Positive
12.23
Positive
Market Momentum
0.64
Negative
61.06
Neutral
87.06
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHVN, the sentiment is Positive. The current price of 14.38 is above the 20-day moving average (MA) of 12.90, above the 50-day MA of 13.62, and above the 200-day MA of 12.23, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 61.06 is Neutral, neither overbought nor oversold. The STOCH value of 87.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BHVN.
Biohaven Ltd. Risk Analysis
Biohaven Ltd. disclosed 64 risk factors in its most recent earnings report. Biohaven Ltd. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biohaven Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.60B | -2.08 | -398.21% | ― | ― | -99.37% | |
56 Neutral | $2.33B | -3.99 | -2271.87% | ― | ― | 49.16% | |
53 Neutral | $1.20B | -8.24 | -29.02% | ― | ― | -23.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.43B | -20.86 | -20.86% | ― | ― | -33.76% | |
45 Neutral | $886.87M | -9.11 | -46.46% | ― | ― | -3.04% |
* Healthcare Sector Average
BHVN
Biohaven Ltd.
15.42
-1.78
-10.35%
CMPS
COMPASS Pathways
11.57
5.25
83.07%
GHRS
GH Research
20.86
6.54
45.67%
ANRO
Alto Neuroscience, Inc.
22.60
8.41
59.27%
RAPP
Rapport Therapeutics, Inc.
25.05
-3.88
-13.41%
SPTX
Seaport Therapeutics, Inc.
19.60
-0.24
-1.21%
Biohaven Ltd. Corporate Events
Product-Related AnnouncementsRegulatory Filings and Compliance
Biohaven’s Vyglxia NDA Resubmission Gains FDA Review
Positive
Oct 22, 2026
On October 22, 2026, Biohaven Ltd. announced that the U.S. Food and Drug Administration has accepted for review its resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, following a prior action letter issued on Nov...
Business Operations and StrategyPrivate Placements and Financing
Biohaven signs Asian IgG degrader licensing deal
Positive
Oct 15, 2026
On October 8, 2026, Biohaven entered a strategic collaboration and license agreement with Ono Pharmaceutical granting Ono exclusive rights to develop and commercialize Biohaven’s MoDE pan IgG degrader portfolio, led by BHV‑1300 and inc...
Business Operations and StrategyLegal Proceedings
Biohaven faces partial FDA hold on BHV-7000 program
Negative
Sep 10, 2026
In January 2024, Biohaven completed its End-of-Phase 2 meeting with the U.S. FDA for BHV-7000, cleared the program to advance into Phase 3, and began enrolling patients in two pivotal randomized, double-blind, placebo-controlled trials in refracto...
Business Operations and StrategyPrivate Placements and Financing
Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals
Positive
Aug 26, 2026
On August 26, 2026, Biohaven Bioscience Ireland Limited, a subsidiary of Biohaven Ltd., entered into a strategic global licensing and collaboration agreement with SK Biopharmaceuticals for Biohaven’s Kv7 ion channel platform, led by the epil...
Executive/Board Changes
Biohaven Appoints John Yetimoglu to Board of Directors
Positive
Aug 7, 2026
On August 3, 2026, Biohaven Ltd.’s board appointed John Yetimoglu as a director, effective August 6, 2026, placing him in the director class whose term runs until the 2027 annual shareholder meeting and naming him to the Nominating and Gover...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.